Harpoon Therapeutics Inc (DELISTED) (HARP:DL)
23.01
0.00 (0.00%)
USD |
NASDAQ |
Mar 11, 16:00
Harpoon Therapeutics Cash from Investing (TTM): 3.283M for Sept. 30, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| September 30, 2023 | 3.283M |
| June 30, 2023 | 9.962M |
| March 31, 2023 | 61.72M |
| December 31, 2022 | 89.74M |
| September 30, 2022 | 94.18M |
| June 30, 2022 | 74.40M |
| March 31, 2022 | 104.71M |
| December 31, 2021 | 34.35M |
| September 30, 2021 | 26.11M |
| June 30, 2021 | 40.57M |
| Date | Value |
|---|---|
| March 31, 2021 | -68.21M |
| December 31, 2020 | -63.63M |
| September 30, 2020 | -76.34M |
| June 30, 2020 | -60.86M |
| March 31, 2020 | -52.98M |
| December 31, 2019 | -69.32M |
| September 30, 2019 | -67.20M |
| June 30, 2019 | -83.20M |
| March 31, 2019 | -52.22M |
| December 31, 2018 | -0.663M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-83.20M
Minimum
Jun 2019
104.71M
Maximum
Mar 2022
-0.1509M
Average
6.622M
Median
Cash from Investing (TTM) Benchmarks
| Merck & Co Inc | -13.10B |
| Axonics Inc | 20.63M |
| Johnson & Johnson | -2.901B |
| Boston Scientific Corp | -2.375B |
| Ambrx Biopharma Inc (DELISTED) | 62.64M |